Dr. Michael McKenna is a neurotologic surgeon with more than 25 years of experience in the field of otolaryngology and neurotology. A graduate of the University of California, San Diego, Dr. McKenna received his medical degree from the University of Southern California School of Medicine in Los Angeles prior to joining Mass. Eye and Ear/Harvard Medical School for his residency in otolaryngology. Subsequently, he received subspecialty training at the House Ear Institute as a neurotology and skull base surgery fellow. Upon competition of his training in 1989, Dr. McKenna joined the Department of Otolaryngology at Harvard Medical School and is now a Professor of Otolaryngology.
At Mass. Eye and Ear, Dr. McKenna serves as the Director of the Division of Otology and Neurotology and as the Director of the Joseph B. Nadol, Jr., M.D. Otolaryngology Surgical Training Laboratory. His clinical practice focuses on otology, neurotology, and skull base surgery. Seeing more than two hundred patients per year with acoustic neuromas and other skull base tumors, his experiences have resulted in numerous clinical publications and invited presentations. Board-certified in otolaryngology—head and neck surgery and neurotology, Dr. McKenna has been recognized both nationally and internationally for his expertise in these areas.
Throughout his career, Dr. McKenna has focused his research on understanding the pathophysiology and pathogenesis of otosclerosis, a bone disease of the human otic capsule that is amongst the most common causes of hearing loss in the general population. He is also actively engaged in research on inner ear drug delivery.
Kinetics of reciprocating drug delivery to the inner ear. Pararas EE, Chen Z, Fiering J, Mescher MJ, Kim ES, McKenna MJ, Kujawa SG, Borenstein JT, Sewell WF. J Control Release. 2011 Jun 10. 152(2):270–7. Epub 2011 Mar 6.
Superior canal dehiscence syndrome associated with the superior petrosal sinus in pediatric and adult patients. McCall AA, McKenna MJ, Merchant SN, Curtin HD, Lee DJ. Otol Neurotol. 2011 Oct. 32(8):1312–9.
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd. Otol Neurotol. 2012 Aug. 33(6):1046–52.
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis. Quesnel AM, Seton M, Merchant SN, Halpin C, McKenna MJ. OtolNeurotol. 2012 Oct;33(8):1308-14.
Correlation of computed tomography with histopathology in otosclerosis. Quesnel AM, Moonis G, Appel J, O'Malley JT, McKenna MJ, Curtin HD, Merchant SN. Otol Neurotol. 2013 Jan. 34(1):22–8.
View a complete list of publications on pubmed.gov »